TY - JOUR
T1 - HER2 Expression in Salivary Gland Carcinomas
T2 - Dependence on Histological Subtype
AU - Glisson, Bonnie
AU - Colevas, A. Dimitrios
AU - Haddad, Robert
AU - Krane, Jeoffrey
AU - El-Naggar, Adel
AU - Kies, Merrill
AU - Costello, Rosemary
AU - Summey, Carmen
AU - Arquette, Matthew
AU - Langer, Corey
AU - Amrein, Philip C.
AU - Posner, Marshall
PY - 2004/2/1
Y1 - 2004/2/1
N2 - Purpose: Previous evaluation of HER2 overexpression in salivary gland cancers indicated an incidence varying between 7 and 56%, with no clear difference among three histologically different subtypes. As part of a Phase II trial of trastuzumab for treatment of incurable salivary gland cancer, we screened 137 tumors for HER2 expression. Experimental Design: Unstained sections of paraffin-embedded tumor samples were stained with p185/HER2 receptor antibody. Tumors with moderate (2+) to strong (3+) complete membrane staining in at least 10% of the tumor cells were scored as positive for overexpression. Results: The overall frequency of overexpression for HER2 was 17% (23 of 137), whereas it was only 8% in the three most common histological subtypes screened. Overexpression was distinctly rare in the most common subtype screened, adenoid cystic carcinoma (4%, 3 of 70). Overexpression was very common in salivary duct cancers; 10 (83%) of 12 were positive for HER2. This observation is consistent with the typical high-grade histological features and aggressive behavior of this subtype as well as with its histogenetic similarity to breast cancer. Analysis based on histogenesis (intercalated duct versus excretory duct) indicated a higher frequency of overexpression in the latter (55%) than in the former (7%). Conclusions: Our overall results suggest that trastuzumab will not have a major role in treatment of salivary gland cancers of intercalated duct origin. Further systematic evaluation of trastuzumab in subtypes of excretory duct origin could be supported.
AB - Purpose: Previous evaluation of HER2 overexpression in salivary gland cancers indicated an incidence varying between 7 and 56%, with no clear difference among three histologically different subtypes. As part of a Phase II trial of trastuzumab for treatment of incurable salivary gland cancer, we screened 137 tumors for HER2 expression. Experimental Design: Unstained sections of paraffin-embedded tumor samples were stained with p185/HER2 receptor antibody. Tumors with moderate (2+) to strong (3+) complete membrane staining in at least 10% of the tumor cells were scored as positive for overexpression. Results: The overall frequency of overexpression for HER2 was 17% (23 of 137), whereas it was only 8% in the three most common histological subtypes screened. Overexpression was distinctly rare in the most common subtype screened, adenoid cystic carcinoma (4%, 3 of 70). Overexpression was very common in salivary duct cancers; 10 (83%) of 12 were positive for HER2. This observation is consistent with the typical high-grade histological features and aggressive behavior of this subtype as well as with its histogenetic similarity to breast cancer. Analysis based on histogenesis (intercalated duct versus excretory duct) indicated a higher frequency of overexpression in the latter (55%) than in the former (7%). Conclusions: Our overall results suggest that trastuzumab will not have a major role in treatment of salivary gland cancers of intercalated duct origin. Further systematic evaluation of trastuzumab in subtypes of excretory duct origin could be supported.
UR - http://www.scopus.com/inward/record.url?scp=10744227930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744227930&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-03-0253
DO - 10.1158/1078-0432.CCR-03-0253
M3 - Article
C2 - 14871971
AN - SCOPUS:10744227930
SN - 1078-0432
VL - 10
SP - 944
EP - 946
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 3
ER -